A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

Hypertrophic Scar Clinical Trial

Official title:

A Randomized, Double-blind, Placebo Self-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preventive Efficacy of AK3280 Cream After Cicatrectomy in Patients With Hypertrophic Scar in China.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05434897
• Other study ID #: AK3287-2001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2022
• Est. completion date: November 2023

Study information

• Verified date: July 2022
• Source: Ark Biosciences Inc.
• Contact: Minyan Guo
• Phone: 86-13651919464
• Email: nora.guo[@]arkbiosciences.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, placebo self-controlled phase I/II clinical study to evaluate the safety, tolerability and preventive efficacy of different doses of AK3280 cream （AK3287 ） after cicatrectomy in Patients with Hypertrophic Scar in China.

Description:

Thirty patients with hypertrophic scar who will scheduled for cicatrectomy and meet the all inclusion criteria and none of exclusion criteria will participate in this study. There will be 3 cohorts for 2%, 4%, 8% doses of AK3287 （AK3280 cream） in turn, and 10 participants in each cohort. Participants in every cohort will receive cicatrectomy on day -5, and their incisions will be divided into 3 parts with equal length after length measurement on day 1, named S1, S2, S3. S1 is proximal, and S3 is distal. AK3280 cream （AK3287 ） or placebo will topically administrated to S1 or S3 randomly, twice a day (BID). In this study, S1 and S3 paired, placebo self-control design will be adopted.

The study includes a 4-week screening period, a 12-week drug observation period, and a 2-week safety follow-up period.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: November 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 1) Patients who sign informed consent before participating in the study.

• 2) Patients aged between 18 and 60 (including 18 and 60).

• 3)Patients who understand and be willing to follow the study procedure and be able to complete the whole process of the study.

• 4) Patients with visible hypertrophic scars in any location other than the face and anterior middle and upper neck caused by trauma or surgery and planned for surgical treatment.

• 5) Patients with postoperative scar length = 6 cm, and preoperative scar length =4cm.

• 6) Women of childbearing age should have negative serum pregnancy test during screening period and on study day 1.

Exclusion Criteria:

• 1) Patients who were systematically treated or topically treated with corticosteroids or immunosuppressants during the 30 days prior to the screening period;

• 2) Patients who accepted systematically chemotherapy during 30 days prior to the screening period;

• 3) Patients whose hypertrophic scars are being locally infected, or with sepsis;

• 4) Hypertrophic scar patients with potential keloid trend or keloid history;

• 5) Patients with autoimmune diseases or immune insufficiency or defects

• 6)Patient with uncontrolled diabetes - HbA1c (glycosylated hemoglobin A1c) = 8% ,with peripheral neuropathy, peripheral arterial atresia, or other vascular diseases;

• 7) Patients with abnormal anticoagulation or coagulation function;

• 8) Patients with atrophic skin diseases, rheumatism or hemopathy ;

• 9) Patients with abnormal liver and kidney function: I. AST (Aspartate Transaminase) or ALT (Alanine Transaminase) > the upper limit of normal, and total bilirubin > the upper limit of normal; Ii. AST or ALT=1.5 times of the upper limit of normal; Iii. Creatinine clearance rate< 60mL/ min ;

• 10) Patients with infectious diseases such as positive antibody of HBV (hepatitis B virus) , HCV (hepatitis B virus), HIV (human immunodeficiency virus) or syphilis;

• 11) The patients or their family have a history of hypersensitivity or allergies to multiple substances, or serious atopic dermatitis, or are not suitable for participate this study by investigator's judgment;

• 12) Patients who are currently or possibly suffering from malignant tumors;

• 13) Patients with definite diagnosis of mental illness with irregular medication;

• 14) Patients received any treatment that may affect wound healing, cicatrization, hemostasis or anti-coagulation, possible interactions with investigational drug within 30 days prior to randomization;

• 15) The investigators judge that patients have safety risk, or cannot complete this study or collect all blood concentration because of patient's general condition, comorbidity or medical history, or abnormal physical examination/vital signs/laboratory tests/electrocardiogram;

• 16) Patients who have received scar ablation or X-ray therapy within the past 6 months;

• 17) Patients have participated in other clinical trials of medicine or devices within 30 days prior to the screening period;

• 18) Pregnant or lactating women;

• 19) Women and men of reproductive age who are not willing to use highly effective contraception during the study period and at least 3 months after the last administration.

Related Conditions & MeSH terms

• Cicatrix, Hypertrophic
• Hypertrophic Scar
• Hypertrophy

Intervention

Drug:
• AK3280 Cream
Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
• Placebo cream
Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use

Locations

Country	Name	City	State
China	Shanghai Ninth People's Hospital,Shanghal JiaoTong University School of Medicine	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Ark Biosciences Inc.	Shanghai Ark Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of adverse events(AE)/ serious adverse events (SAEs)	Adverse Events occurring from day1 to last visit will be assessed and graded according to Common Terminology Criteria for Adverse Events version 5.0.	Up to 14 weeks
Primary	Number of participants with abnormal Skin Examination	The skin examination should be performed under sufficient light and at room temperature , including skin lesion, inflammation, allergy, Scar hyperplasia.	Up to 14 weeks
Primary	Number of participants with abnormal vital signs	Vital signs: include pulse, respiration, body temperature and blood pressure	Up to 14 weeks
Primary	Number of participants with abnormal Physical examination findings	Physical examination : include height, weight, head and neck, mouth, chest, abdomen, lymph nodes, nerves and mind, limbs and other sites	Up to 14 weeks
Primary	Number of participants with abnormal 12-lead ECG readings		Up to 14 weeks
Primary	Number of participants with abnormal laboratory test results	Laboratory tests:include blood routine examination, blood biochemistry ,urine routine test and coagulation function	Up to 14 weeks
Secondary	Within 12 weeks of topical administration, the proportion of scar hyperplasia/recurrence compared in S1 and S3 segment	There are 4 items in the VSS scale(Vancouver Scar Scale) , Vascularity? Pigmentation? Pliability and Height. A total of 13 points, with minimum 0 indicating normal skin and maximum 13 indicating the most scarring and worst appearance. Two trained and skilled physicians are required to objectively evaluate the scar of all subjects. The scar was observed after pressing with a special glass slide for 2 seconds, and the average score of both was used as the final score of VSS to reduce subjective bias.; Scar hyperplasia/recurrence was defined as the Height item score of the VSS scale =2.; If two investigators had different scores in Height item, for safety, the higher score would be final result.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Within 12 weeks of topical administration, the change of VSS (Vancouver Scar Scale ) total score compared in S1 and S3 segment from baseline	There are 4 items in the VSS scale(Vancouver Scar Scale) , Vascularity? Pigmentation? Pliability and Height. A total of 13 points, with minimum 0 indicating normal skin and maximum 13 indicating the most scarring and worst appearance. Two trained and skilled physicians are required to objectively evaluate the scar of all subjects. The scar was observed after pressing with a special glass slide for 2 seconds, and the average score of both was used as the final score of VSS to reduce subjective bias.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Within 12 weeks of topical administration, the change of mean thickness by 3D photography compared in S1 and S3 segment from baseline	Taking 5 points in each segment can automatically get the thickness of each point by 3D photography and calculate the average thickness.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Within 12 weeks of topical administration, the change of surface area per centimeter by 3D photography compared in S1 and S3 segment from baseline	Surface area can be obtained directly by 3D photography,then calculate the surface area per centimeter.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Within 12 weeks of topical administration, the change of volume per centimeter by 3D photography compared in S1 and S3 segment from baseline	Volume can be obtained directly by 3D photography,then calculate the volume per centimeter.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Within 12 weeks of topical administration, the change of blood flow in laser speckle imaging system compared in S1 and S3 segment from baseline	Blood perfusion of capillary of scar, para-scar and normal tissue will be tested by laser speckle imaging system to evaluate scar recurrence compared S1 with S3.	4 weeks, 8 weeks, 12 weeks, and unscheduled visits (up to 14 weeks)
Secondary	Cmax (Maximum observed concentration) of AK3280 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	Ctrough (trough level concentration) of AK3280 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	Tmax (Time of peak plasma concentration) of AK3280 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	AUC0-t (Area under the concentration-time curve from time zero to the last measurable concentration ) of AK3280 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	CL/F (apparent clearance) of AK3280 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	Cmax of AK3280 M2 after topical administration of AK3280 onitment.	Four metabolites (M1-M4) were detected in human plasma collected after oral administration of AK3280. M2 is the most abundant metabolite circulating in the blood, also found in urine.	Up to 14 weeks
Secondary	Ctrough of AK3280 M2 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	Tmax of AK3280 M2 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	AUC0-t of AK3280 M2 after topical administration of AK3280 onitment.		Up to 14 weeks
Secondary	CL/F of AK3280 M2 after topical administration of AK3280 onitment.		Up to 14 weeks